Racial Disparities in Treatment and Outcomes of Pediatric Hepatoblastoma

J Pediatr Hematol Oncol. 2024 Aug 1;46(6):e381-e386. doi: 10.1097/MPH.0000000000002918. Epub 2024 Jul 5.

Abstract

Pediatric Hepatoblastoma is a rare malignancy of the liver. This study used the National Cancer Database (NCDB) to identify 1068 patients diagnosed with hepatoblastoma from 2004 to 2020. χ 2 and Analysis of Variance testing, as well as Kaplan-Meier, Cox Regression, and multinomial logistic regression models were used. Data was analyzed using SPSS version 27, and statistical significance was set at α=0.05. Our results found Black patients experienced a significantly lower median survival rate compared with White patients, a difference which persisted after controlling for covariates. Black patients were also less likely to receive surgery and chemotherapy and more likely to be from low-income households than White patients. White patients had a significantly shorter inpatient hospital stay compared to Black patients and were more likely to receive treatment at more than 1 CoC accredited facility. There was no significant difference in grade, size of tumor, metastasis, or time of diagnosis to surgery. This study showed Black patients experienced inferior overall survival when diagnosed and treated for hepatoblastoma compared to White patients.

MeSH terms

  • Adolescent
  • Black or African American / statistics & numerical data
  • Child
  • Child, Preschool
  • Female
  • Healthcare Disparities* / ethnology
  • Healthcare Disparities* / statistics & numerical data
  • Hepatoblastoma* / ethnology
  • Hepatoblastoma* / mortality
  • Hepatoblastoma* / pathology
  • Hepatoblastoma* / therapy
  • Humans
  • Infant
  • Infant, Newborn
  • Liver Neoplasms* / ethnology
  • Liver Neoplasms* / mortality
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / therapy
  • Male
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome
  • White People* / statistics & numerical data